Comparison of Dexmedetomidine and Bupivacaine With Bupivacaine Alone on the Quality of Ultrasonography Guided Fascia Iliaca Compartment Block in Adults Undergoing Femur Fracture Fixation Surgery

Dexmedetomidine and Bupivacaine With Bupivacaine in Ultrasonography Guided Fascia Iliaca Compartment Block in Adults

Sponsors

Lead sponsor: Hamidreza Mahboobi

Source Hormozgan University of Medical Sciences
Brief Summary

Few studies have reported the efficacy of adding dexmedetomidine to bupivacain for fascia illiaca compartment black. Comparison of dexmedetomidine and bupivacaine with bupivacaine alone on the quality of ultrasonography guided fascia iliaca compartment block in adults undergoing femur fracture fixation surgery at 2014.

Overall Status Unknown status
Start Date June 2015
Completion Date December 2016
Primary Completion Date December 2016
Phase Phase 3
Study Type Interventional
Primary Outcome
Measure Time Frame
Pain 24 hours
Secondary Outcome
Measure Time Frame
Respiratory depression 24 hours
Hypotension 24 hours
Baradycardia 24 hours
Enrollment 60
Condition
Intervention

Intervention type: Drug

Intervention name: Dexmedetomidine

Description: dexmedetomidine plus placebo

Arm group label: Dexmedetomidine and bupivacaine

Intervention type: Drug

Intervention name: Bupivacaine

Description: dexmedetomidine and Bupivacaine

Eligibility

Criteria:

Inclusion Criteria:

- Adults with femural fracture

Exclusion Criteria:

- Hypersensitivity to drugs

- Neurological diseases

- Coagulation abnormalities

- Infection at the site of block

Gender: All

Minimum age: 14 Years

Maximum age: N/A

Healthy volunteers: No

Overall Official
Last Name Role Affiliation
Nasim Abdi Principal Investigator Hormozgan University of Medical Sciences
Overall Contact

Last name: Hamidreza Mahboobi

Phone: 9172121995

Phone ext: +98

Email: [email protected]

Location
facility status contact investigator Shahid Mohammadi hospital Hamidreza Mahboobi 09809364300250 [email protected] Hamidreza Mahboobi Principal Investigator
Location Countries

Iran, Islamic Republic of

Verification Date

October 2016

Responsible Party

Responsible party type: Sponsor-Investigator

Investigator affiliation: Hormozgan University of Medical Sciences

Investigator full name: Hamidreza Mahboobi

Investigator title: Investigator

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Arm group label: Bupivacaine

Arm group type: Experimental

Description: 30cc of 0.25% bupivacaine

Arm group label: Dexmedetomidine and bupivacaine

Arm group type: Active Comparator

Description: 30cc of 0.25% bupivacaine and 2mg/kg dexmedetomidine

Patient Data No
Study Design Info

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: Single (Outcomes Assessor)

Source: ClinicalTrials.gov